DOP2023000195A - Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática - Google Patents
Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmáticaInfo
- Publication number
- DOP2023000195A DOP2023000195A DO2023000195A DO2023000195A DOP2023000195A DO P2023000195 A DOP2023000195 A DO P2023000195A DO 2023000195 A DO2023000195 A DO 2023000195A DO 2023000195 A DO2023000195 A DO 2023000195A DO P2023000195 A DOP2023000195 A DO P2023000195A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- plasma
- kallycrenein
- inhibitors
- carboxamide derivatives
- heteroaromatic carboxamide
- Prior art date
Links
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- -1 Heteroaromatic carboxamides Chemical class 0.000 abstract 1
- 102000003827 Plasma Kallikrein Human genes 0.000 abstract 1
- 108090000113 Plasma Kallikrein Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Carboxamidas heteroaromáticas de la Fórmula (I), , en donde Y, R, y Ar son como se definen en la descripción y las reivindicaciones, y sales aceptables desde el punto de vista farmacéutico de estos se pueden usar en los métodos para el tratamiento de enfermedades que pueden verse influenciadas por la inhibición de la calicreína plasmática.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20157259 | 2020-02-13 | ||
| PCT/EP2021/053286 WO2021160718A1 (en) | 2020-02-13 | 2021-02-11 | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2023000195A true DOP2023000195A (es) | 2023-10-31 |
Family
ID=69591572
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2022000157A DOP2022000157A (es) | 2020-02-13 | 2022-08-03 | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática |
| DO2023000195A DOP2023000195A (es) | 2020-02-13 | 2023-09-14 | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2022000157A DOP2022000157A (es) | 2020-02-13 | 2022-08-03 | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US11760745B2 (es) |
| EP (1) | EP4103562A1 (es) |
| JP (2) | JP7230277B2 (es) |
| KR (1) | KR20220141333A (es) |
| CN (2) | CN115052873A (es) |
| AR (1) | AR121341A1 (es) |
| AU (1) | AU2021218952A1 (es) |
| BR (1) | BR112022013979A2 (es) |
| CA (1) | CA3168690A1 (es) |
| CL (2) | CL2022002101A1 (es) |
| CO (1) | CO2022011254A2 (es) |
| CR (1) | CR20220382A (es) |
| DO (2) | DOP2022000157A (es) |
| EC (1) | ECSP22062410A (es) |
| IL (1) | IL295125A (es) |
| JO (1) | JOP20220186A1 (es) |
| MX (1) | MX2022009941A (es) |
| PE (2) | PE20221591A1 (es) |
| TW (1) | TW202144330A (es) |
| WO (1) | WO2021160718A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202144331A (zh) | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| US20050090529A1 (en) | 2003-07-31 | 2005-04-28 | Pfizer Inc | 3,5 Disubstituted indazole compounds with nitrogen-bearing 5-membered heterocycles, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation |
| JP2005089362A (ja) | 2003-09-17 | 2005-04-07 | Sumitomo Chemical Co Ltd | アリールピラゾリン化合物及びその用途 |
| US8658685B2 (en) | 2008-01-31 | 2014-02-25 | Activesite Pharmaceuticals, Inc. | Methods for treatment of kallikrein-related disorders |
| WO2013111108A1 (en) | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| AU2014270152B9 (en) | 2013-05-23 | 2018-03-08 | Kalvista Pharmaceuticals Limited | Heterocyclic derivates |
| EP3368529B1 (en) | 2015-10-27 | 2022-04-06 | Boehringer Ingelheim International GmbH | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| US10640486B2 (en) | 2015-10-27 | 2020-05-05 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| SI3464271T1 (sl) | 2016-05-31 | 2020-10-30 | Kalvista Pharmaceuticals Limited | Derivati pirazola kot inhibitorji plazemskega kalikreina |
| WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| CN110546146B (zh) | 2017-04-21 | 2023-02-21 | 勃林格殷格翰国际有限公司 | 作为血浆激肽释放酶抑制剂的杂芳基羧酰胺衍生物 |
| WO2020035540A1 (en) | 2018-08-16 | 2020-02-20 | Boehringer Ingelheim International Gmbh | Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors |
| TW202144331A (zh) | 2020-02-13 | 2021-12-01 | 德商百靈佳殷格翰國際股份有限公司 | 作為血漿激肽釋放酶抑制劑之雜芳族甲醯胺衍生物 |
-
2021
- 2021-02-09 TW TW110104875A patent/TW202144330A/zh unknown
- 2021-02-11 AU AU2021218952A patent/AU2021218952A1/en active Pending
- 2021-02-11 JP JP2022514811A patent/JP7230277B2/ja active Active
- 2021-02-11 BR BR112022013979A patent/BR112022013979A2/pt unknown
- 2021-02-11 CA CA3168690A patent/CA3168690A1/en active Pending
- 2021-02-11 MX MX2022009941A patent/MX2022009941A/es unknown
- 2021-02-11 IL IL295125A patent/IL295125A/en unknown
- 2021-02-11 US US17/173,213 patent/US11760745B2/en active Active
- 2021-02-11 WO PCT/EP2021/053286 patent/WO2021160718A1/en active Application Filing
- 2021-02-11 JO JOP/2022/0186A patent/JOP20220186A1/ar unknown
- 2021-02-11 PE PE2022001696A patent/PE20221591A1/es unknown
- 2021-02-11 CR CR20220382A patent/CR20220382A/es unknown
- 2021-02-11 CN CN202180011395.3A patent/CN115052873A/zh active Pending
- 2021-02-11 PE PE2023001617A patent/PE20231985A1/es unknown
- 2021-02-11 KR KR1020227031639A patent/KR20220141333A/ko unknown
- 2021-02-11 EP EP21706489.8A patent/EP4103562A1/en active Pending
- 2021-02-11 CN CN202310088017.6A patent/CN116120287A/zh active Pending
- 2021-02-12 AR ARP210100385A patent/AR121341A1/es unknown
-
2022
- 2022-08-03 DO DO2022000157A patent/DOP2022000157A/es unknown
- 2022-08-04 CL CL2022002101A patent/CL2022002101A1/es unknown
- 2022-08-10 CO CONC2022/0011254A patent/CO2022011254A2/es unknown
- 2022-08-10 EC ECSENADI202262410A patent/ECSP22062410A/es unknown
-
2023
- 2023-02-15 JP JP2023021625A patent/JP2023067881A/ja active Pending
- 2023-04-28 CL CL2023001244A patent/CL2023001244A1/es unknown
- 2023-08-25 US US18/455,865 patent/US20240002363A1/en active Pending
- 2023-09-14 DO DO2023000195A patent/DOP2023000195A/es unknown
- 2023-09-18 US US18/468,885 patent/US20240076286A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11760745B2 (en) | 2023-09-19 |
| JP2022543494A (ja) | 2022-10-12 |
| EP4103562A1 (en) | 2022-12-21 |
| MX2022009941A (es) | 2022-09-12 |
| PE20231985A1 (es) | 2023-12-12 |
| US20240076286A1 (en) | 2024-03-07 |
| KR20220141333A (ko) | 2022-10-19 |
| WO2021160718A1 (en) | 2021-08-19 |
| US20240002363A1 (en) | 2024-01-04 |
| AU2021218952A1 (en) | 2022-07-28 |
| JOP20220186A1 (ar) | 2023-01-30 |
| AR121341A1 (es) | 2022-05-11 |
| CR20220382A (es) | 2022-09-16 |
| CN116120287A (zh) | 2023-05-16 |
| TW202144330A (zh) | 2021-12-01 |
| DOP2022000157A (es) | 2022-09-15 |
| JP7230277B2 (ja) | 2023-02-28 |
| CL2023001244A1 (es) | 2023-11-03 |
| JP2023067881A (ja) | 2023-05-16 |
| US20210292301A1 (en) | 2021-09-23 |
| CO2022011254A2 (es) | 2022-08-19 |
| IL295125A (en) | 2022-09-01 |
| BR112022013979A2 (pt) | 2022-10-11 |
| PE20221591A1 (es) | 2022-10-10 |
| ECSP22062410A (es) | 2022-09-30 |
| CA3168690A1 (en) | 2021-08-19 |
| CL2022002101A1 (es) | 2023-01-27 |
| CN115052873A (zh) | 2022-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000038A (es) | COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
| CL2018001145A1 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| CO2022008091A2 (es) | Inhibidores de kras g12c | |
| AR111495A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak | |
| NI201600165A (es) | Inhibidores de desmetilasa 1 específica a lisina | |
| UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
| DOP2023000195A (es) | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática | |
| DOP2024000039A (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| CL2021001461A1 (es) | Moduladores de trex1 | |
| PA8821301A1 (es) | Inhibidores a base de hidroxamato de desacetilasas b | |
| DOP2012000058A (es) | Agente terapeutico para trastornos del estado de animo | |
| SV2017005354A (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| CO2019010559A2 (es) | Composiciones y compuestos terapéuticos y métodos para utilizarlos | |
| BR112022021381A2 (pt) | Compostos para o tratamento de sars | |
| UY38665A (es) | Agentes antiproliferativos para el tratamiento de pah | |
| CL2022000875A1 (es) | Inhibidores del factor d del complemento para administración oral | |
| CO2021008535A2 (es) | Compuestos de quinolina como inhibidores de quinasas tam y met | |
| CL2022000889A1 (es) | Inhibidores del factor d del complemento para administración oral | |
| AR121340A1 (es) | Derivados de carboxamida heteroaromáticos como inhibidores de calicreína plasmática | |
| ECSP23088732A (es) | Moduladores de trex1 | |
| EA201990109A1 (ru) | Митохондриальные ингибиторы для лечения пролиферативных нарушений | |
| BR112022003768A2 (pt) | Compostos inibidores de perk | |
| AR127127A1 (es) | NUEVOS DERIVADOS DE PIRIDODIAZEPINAS COMO PAM DE GABAA g1 | |
| BR112022020295A2 (pt) | Compostos para o tratamento de sars |